Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 6, 2014, Pages 1141-1157

  Van Binnebeek, Sofie ^a,b   Baete, Kristof ^a,b   Vanbilloen, Bert ^a,b   Terwinghe, Christelle ^a,b   Koole, Michel ^c   Mottaghy, Felix M ^d,e   Clement, Paul M ^a,f   Mortelmans, Luc ^a,b   Haustermans, Karin ^a,f   Van Cutsem, Eric ^a,f   Verbruggen, Alfons ^f   Bogaerts, Kris ^g   Verslype, Chris ^a,f   Deroose, Christophe M ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g KU LEUVEN   (Belgium)

Author keywords

Dosimetry; PRRT; Renal function

Indexed keywords

EDETATE CHROMIUM CR 51; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; TETRAXETAN DEXTRO 1 PHENYLALANINE 3 TYROSINE OCTREOTIDE Y 90; UNCLASSIFIED DRUG; EDOTREOTIDE; OCTREOTIDE; YTTRIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DISEASE COURSE; DOSE RESPONSE; DOSIMETRY; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; ISOTOPE LABELING; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; METASTASIS; MIDDLE AGED; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RADIOTHERAPY; RISK FACTOR; WHOLE BODY IMAGING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIGESTIVE SYSTEM NEOPLASMS; KIDNEY; KIDNEY FUNCTION TEST; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROCEDURES; RADIATION DOSE; RADIATION RESPONSE; RADIOMETRY; SCINTISCANNING;

ADULT; AGED; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY; KIDNEY FUNCTION TESTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 84900802150     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2670-x     Document Type: Article

References (41)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72. doi: 10.1016/S1470-2045(07)70410-2.
2. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610-6.
3. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416-23. doi: 10.1200/JCO.2010.33.7873.
4. Bushnell Jr DL, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652-9. doi: 10.1200/JCO.2009.22.8585.
5. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-30. doi: 10.1200/JCO.2007.15.2553.
6. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125-35. doi: 10.1007/s00259-011- 1902-1.
7. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:92S-8.
8. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-16. doi: 10.1007/s00259-002-1023-y.
9. de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med. 2002;43:617-20.
10. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847-56. doi: 10.1007/s00259-008- 0778-1.
11. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-8. doi: 10.1007/s00259-003-1117-1.
12. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46 Suppl 1:83S-91.
13. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-47.
14. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552-4. doi: 10.1007/s002590100599.
15. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447-9.
16. Stoffel MP, Pollok M, Fries J, Baldamus CA. Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma. Nephrol Dial Transplant. 2001;16:1082-3.
17. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847-51.
18. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46 Suppl 1:99S-106.
19. Van Binnebeek S, Deroose CM, Baete K, Terwinghe C, Vanbilloen B, Koole M, et al. Altered biodistribution of somatostatin analogues after first cycle of peptide receptor radionuclide therapy. J Clin Oncol. 2011;29:e579-81. doi: 10.1200/JCO.2010.34.3384.
20. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303-11.
21. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467-75.
22. Förster GJ, Engelbach MJ, Brockmann JJ, Reber HJ, Buchholz HG, Macke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med. 2001;28:1743-50. doi: 10.1007/s002590100628.
23. Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386-92. doi: 10.1007/s00259-004-1561-6.
24. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-7.
25. Van Binnebeek S, Baete K, Terwinghe C, Vanbilloen B, Haustermans K, Mortelmans L, et al. Significant impact of transient deterioration of renal function on dosimetry in PRRT. Ann Nucl Med. 2013;27:74-7. doi: 10.1007/s12149-012-0651-y.
26. Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008;35:1123-34.
27. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113-47.
28. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response - implications for radionuclide therapy. J Nucl Med. 2008;49:1884-99.
29. Thames HD. A new model of proliferative response to fractionated irradiation. Radiother Oncol. 1988;13:311-3.
30. Konijnenberg MW. Is the renal dosimetry for [90Y-DOTA0, Tyr3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm. 2003;18:619-25. doi: 10.1089/108497803322287718.
31. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766-72. doi: 10.1373/clinchem.2006.077180.
32. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-12.
33. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417-8.
34. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-22.
35. Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QK, et al. Somatostatin-based radiopeptide therapy with [Lu-DOTA]-TOC versus [Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013. doi: 10.1007/s00259-013-2559-8.
36. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-22. doi: 10.1007/s00259-002-1050-8.
37. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-62. doi: 10.1200/JCO.2005.08.066.
38. Fabbri C, Sarti G, Cremonesi M, Ferrari M, Di Dia A, Agostini M, et al. Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm. 2009;24:145-54. doi: 10.1089/cbr.2008.0543.
39. Lhommel R, van Elmbt L, Goffette P, Van den Eynde M, Jamar F, Pauwels S, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging. 2010;37:1654-62. doi: 10.1007/s00259-010-1470-9.
40. D'Arienzo M, Chiaramida P, Chiacchiararelli L, Coniglio A, Cianni R, Salvatori R, et al. 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun. 2012;33:633-40. doi: 10.1097/MNM.0b013e3283524220.
41. Walrand S, Jamar F, van Elmbt L, Lhommel R, Bekonde EB, Pauwels S. 4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET. J Nucl Med. 2010;51:1969-73. doi: 10.2967/jnumed.110.080093.